Is the price fair?
What ALKS's price assumes
Alkermes plc trades at 50.5× earnings against 24.3× for the median Drug Manufacturers - Specialty & Generic name, more expensive than its own group.
50.5
Trailing P/E · Drug Manufacturers - Specialty & Generic median 24.3 · 2.08× the median: the market pays up for this one
- Price / sales
- 3.76
Price / sales · as of 2026-Q1
- Free cash flow yield
- 2.5%
Free cash flow yield · Drug Manufacturers - Specialty & Generic median 4.4%
- Growth the price implies
- +15%
Growth the price implies · The price pays for +15% free cash flow growth a year for a decade; revenue has grown +12% a year over the last three.
Details›
- Price / book2026-Q1
- 3.36
- EV / EBIT2026-Q1
- 36.7
- EV / sales2026-Q1
- 4.51
- Healthcare median P/E362 names
- 29.9
- Drug Manufacturers - Specialty & Generic median P/E32 names
- 24.3
- Free cash flow, trailing twelve months
- $222M
- Market capitalisation
- $8.81B
- 3-year revenue growth
- +12%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Drug Manufacturers - Specialty & Generic
Ranks #20 of 29 by Smart Score